Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells

This study demonstrates that reactivation of the mitochondrial fission protein DRP1, driven by a c-Myc-CDK6 signaling axis, mediates resistance to MEK inhibitors in pancreatic cancer, suggesting that targeting mitochondrial fission could overcome therapeutic resistance.

The Gist

Imagine your cells are like busy factories. Inside these factories, there are tiny power plants called mitochondria that keep everything running. Usually, these power plants can split apart (fission) or merge together, kind of like how a school of fish might break into smaller groups or come together as one big school.

In many pancreatic cancers, a broken switch (a mutated gene called RAS) tells the factory to keep splitting these power plants apart constantly. This "splitting" is driven by a worker named DRP1. The paper tells us that when these power plants are constantly splitting, the cancer factory grows faster and becomes more dangerous.

The Problem: The Factory Fights Back
Doctors often try to stop this cancer by using a drug called trametinib. Think of trametinib as a security guard who blocks the main road (the MAPK pathway) that usually tells DRP1 to start splitting the power plants.

However, the cancer cells are tricky. The researchers found that some cancer cells learned to ignore the security guard. Even though the main road was blocked, these "resistant" cells found a secret backdoor. They started using a different set of instructions involving two other workers, c-Myc and CDK6. These two workers took over and told DRP1 to keep splitting the power plants anyway, even without the usual signal.

The Evidence
The scientists looked closely at these resistant cells and saw two things:

1. More DRP1: The cells had more of the "splitting" worker than the normal, sensitive cells.
2. Smaller Power Plants: Because DRP1 was working overtime, the mitochondria in the resistant cells were chopped up into many tiny, separate pieces, whereas the sensitive cells had larger, more connected power plants.

The Solution: Cutting the Power
To prove this was the cause of the resistance, the researchers tried two things:

• They blocked the secret backdoor (stopping c-Myc and CDK6).
• They removed the DRP1 worker entirely.

When they did this, the resistant cells stopped growing, or they became vulnerable to the original drug (trametinib) again. It was like cutting the power to the secret backdoor; the factory couldn't keep running on its own anymore.

The Bottom Line
This study shows that the cancer's ability to keep splitting its power plants (via DRP1) is a key reason it survives the drug treatment. The researchers suggest that if we can stop this splitting process, we might be able to defeat the drug-resistant cancer cells.

Technical Summary

Technical Summary: Reactivation of DRP1 in MEK Inhibitor Resistance

Problem Statement
In RAS-mutant tumors, the MAPK pathway drives mitochondrial fission through the phosphorylation of the GTPase DRP1 by ERK. While DRP1 activity is established as tumor-promoting in pancreatic and other RAS-driven cancers, its specific role in the development of therapeutic resistance to MAPK pathway inhibitors remains undefined. This study addresses the gap in understanding how mitochondrial dynamics contribute to resistance against MEK inhibitors, specifically trametinib, in pancreatic cancer.

Methodology
The researchers established a panel of patient-derived pancreatic cancer cell lines engineered to be resistant to the MEK inhibitor trametinib. To investigate the role of DRP1 in this resistance phenotype, the team employed a multi-faceted approach:

• Imaging and Morphology: Immunofluorescence imaging was used to visualize mitochondrial structure.
• Functional Assays: In vitro growth assays and orthotopic xenograft models were utilized to assess tumor growth and drug response.
• Molecular Interventions: The study utilized both genetic deletion and pharmacological inhibition to target DRP1 and its upstream regulators, specifically c-Myc and CDK6.

Key Results
The investigation yielded several critical findings regarding the mechanism of resistance:

1. DRP1 Upregulation: Trametinib-resistant cells demonstrated significantly increased expression and phosphorylation of DRP1 compared to their sensitive counterparts.
2. Mitochondrial Morphology: Quantitative analysis revealed that mitochondria in resistant cells are morphologically distinct and relatively smaller than those in sensitive cells treated with trametinib, indicating a state of active fission.
3. Signaling Axis Identification: The study identified that the reactivation of DRP1 phosphorylation in the absence of MAPK signaling is driven by a c-Myc-CDK6 signaling axis. Both genetic and pharmacological inhibition of c-Myc and CDK6 were sufficient to block DRP1 phosphorylation in resistant cells.
4. Functional Necessity: Deletion of DRP1 in resistant cell lines resulted in either direct growth inhibition or re-sensitization to trametinib, confirming the protein's functional role in maintaining the resistant state.

Significance and Claims
The paper concludes that DRP1 contributes directly to drug resistance in pancreatic cancer cells treated with MEK inhibitors. The authors posit that the reactivation of mitochondrial fission via the c-Myc-CDK6 axis allows tumor cells to bypass the blockade of MAPK signaling. Consequently, the study suggests that targeting mitochondrial fission, specifically through DRP1 inhibition, represents a promising therapeutic strategy to combat resistance to both MAPK and RAS inhibitors. The findings underscore the importance of mitochondrial dynamics as a potential vulnerability in overcoming therapeutic resistance in RAS-driven malignancies.